CN100418971C - 作为抗癌剂的杂芳基-稠合的嘧啶基化合物 - Google Patents

作为抗癌剂的杂芳基-稠合的嘧啶基化合物 Download PDF

Info

Publication number
CN100418971C
CN100418971C CNB2004800148198A CN200480014819A CN100418971C CN 100418971 C CN100418971 C CN 100418971C CN B2004800148198 A CNB2004800148198 A CN B2004800148198A CN 200480014819 A CN200480014819 A CN 200480014819A CN 100418971 C CN100418971 C CN 100418971C
Authority
CN
China
Prior art keywords
compound
alkyl
hydrogen
heteroaryl
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB2004800148198A
Other languages
English (en)
Chinese (zh)
Other versions
CN1798749A (zh
Inventor
W·王
L·M·拉格尼顿
R·N·康斯坦丁
M·T·伯哥
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NOVARTIS VACCINES and DIAGNOSTIC Inc
Original Assignee
Novartis Vaccines and Diagnostics Inc
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines and Diagnostics Inc, Chiron Corp filed Critical Novartis Vaccines and Diagnostics Inc
Publication of CN1798749A publication Critical patent/CN1798749A/zh
Application granted granted Critical
Publication of CN100418971C publication Critical patent/CN100418971C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/81—Packaged device or kit

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNB2004800148198A 2003-05-30 2004-05-27 作为抗癌剂的杂芳基-稠合的嘧啶基化合物 Expired - Fee Related CN100418971C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47468403P 2003-05-30 2003-05-30
US60/474,684 2003-05-30

Publications (2)

Publication Number Publication Date
CN1798749A CN1798749A (zh) 2006-07-05
CN100418971C true CN100418971C (zh) 2008-09-17

Family

ID=33551504

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB2004800148198A Expired - Fee Related CN100418971C (zh) 2003-05-30 2004-05-27 作为抗癌剂的杂芳基-稠合的嘧啶基化合物

Country Status (10)

Country Link
US (2) US7345046B2 (enExample)
EP (1) EP1636238A1 (enExample)
JP (1) JP2007500237A (enExample)
KR (1) KR20060054187A (enExample)
CN (1) CN100418971C (enExample)
AU (1) AU2004247650A1 (enExample)
CA (1) CA2526217A1 (enExample)
MX (1) MXPA05012706A (enExample)
TW (1) TW200505454A (enExample)
WO (1) WO2004111058A1 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004078758A1 (en) * 2003-03-07 2004-09-16 Astrazeneca Ab Novel fused heterocycles and uses thereof
AR050920A1 (es) * 2003-03-07 2006-12-06 Astrazeneca Ab Enantiomeros de heterociclos fusionados seleccionados y usos de los mismos
WO2005061519A1 (en) * 2003-12-19 2005-07-07 Takeda San Diego, Inc. Kinase inhibitors
DE602005012069D1 (de) * 2004-04-06 2009-02-12 Novartis Vaccines & Diagnostic Inhibitoren von mitotischem kinesin
WO2005105788A1 (en) * 2004-04-23 2005-11-10 Takeda San Diego, Inc. Indole derivatives and use thereof as kinase inhibitors
MX2007000809A (es) * 2004-07-22 2007-03-21 Astrazeneca Ab Pirimidonas fusionadas utiles en el tratamiento y la prevencion de cancer.
US7550598B2 (en) * 2004-08-18 2009-06-23 Takeda Pharmaceutical Company Limited Kinase inhibitors
AR050921A1 (es) * 2004-08-18 2006-12-06 Astrazeneca Ab Heterociclos fusionados seleccionados y usos de los mismos
KR20070046176A (ko) * 2004-08-18 2007-05-02 아스트라제네카 아베 특정 융합 피리미돈의 거울상이성질체 및 이의 암 치료 및예방에 있어서의 용도
US7713973B2 (en) * 2004-10-15 2010-05-11 Takeda Pharmaceutical Company Limited Kinase inhibitors
CA2599899A1 (en) * 2005-03-09 2006-09-21 Schering Corporation Fused thieno [2, 3-b] pyridine and thiazolo [5, 4-b] pyridine compounds for inhibiting ksp kinesin activity
MX2007010973A (es) * 2005-03-09 2007-09-19 Schering Corp Compuestos para inhibir la actividad de cinesina de ksp.
US7608643B2 (en) 2005-03-09 2009-10-27 Schering Corporation Compounds for inhibiting KSP kinesin activity
DE102005011822A1 (de) * 2005-03-15 2006-09-21 Merck Patent Gmbh Phthalazinone
NZ563909A (en) 2005-05-13 2011-10-28 Virochem Pharma Inc Thiophene derivatives and their use for the treatment or prevention of flavivirus infections
AU2011205048B2 (en) * 2005-05-13 2013-05-02 Virochem Pharma Inc. Compounds and methods for the treatment or prevention of flavivirus infections
US8119655B2 (en) * 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
SG158147A1 (en) 2006-10-09 2010-01-29 Takeda Pharmaceutical Kinase inhibitors
EP2131849B1 (en) * 2007-03-02 2011-10-26 The University Of Wollongong Compositions and methods for delivery of anti-cancer agents
TW200902016A (en) * 2007-05-22 2009-01-16 Taigen Biotechnology Co Ltd Kinesin inhibitors
JP2010530885A (ja) 2007-06-22 2010-09-16 アークル インコーポレイテッド キナゾリノン化合物およびその使用方法
PE20091669A1 (es) 2007-12-21 2009-12-06 Exelixis Inc Benzofuropirimidinonas
US8940742B2 (en) * 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
SG10201902074UA (en) 2013-10-04 2019-04-29 Infinity Pharmaceuticals Inc Heterocyclic compounds and uses thereof
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN113616656B (zh) 2014-03-19 2023-02-17 无限药品股份有限公司 用于治疗PI3K-γ介导的障碍的杂环化合物
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CA2972787A1 (en) * 2014-12-29 2016-07-07 New Mexico Tech Research Foundation Synthetic rigidin analogues as anticancer agents, salts, solvates and prodrugs thereof, and method of producing same
AU2016322552B2 (en) 2015-09-14 2021-03-25 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
US10221191B2 (en) 2015-12-22 2019-03-05 SHY Therapeutics LLC Compounds for the treatment of cancer and inflammatory disease
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
SG11201911929XA (en) 2017-06-21 2020-01-30 SHY Therapeutics LLC Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
WO2020132071A1 (en) 2018-12-19 2020-06-25 Shy Therapeutics. Llc Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and f1brotic disease

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001098278A1 (en) * 2000-06-21 2001-12-27 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
WO2003039460A2 (en) * 2001-11-07 2003-05-15 Merck & Co., Inc. Mitotic kinesin inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0720969B2 (ja) * 1988-03-02 1995-03-08 吉富製薬株式会社 ３，４―ジヒドロチエノ〔２，３―ｄ〕ピリミジン化合物およびその医薬用途
CZ20031910A3 (cs) 2000-12-11 2003-12-17 Tularik Inc. Sloučenina s antagonistickými účinky na CXCR3 a farmaceutický postředek
US7244723B2 (en) 2001-12-06 2007-07-17 Merck & Co., Inc. Substituted furopyrimidinones as a mitotic kinesin inhibitors
AU2002351183B2 (en) 2001-12-06 2008-05-08 Merck Sharp & Dohme Corp. Mitotic kinesin inhibitors
WO2003050064A2 (en) 2001-12-06 2003-06-19 Merck & Co., Inc. Mitotic kinesin inhibitors
AU2002363960B2 (en) 2001-12-06 2008-07-10 Merck Sharp & Dohme Corp. Mitotic kinesin inhibitors
WO2004039774A2 (en) 2002-05-23 2004-05-13 Merck & Co., Inc. Mitotic kinesin inhibitors
EP1513820A4 (en) 2002-05-23 2006-09-13 Cytokinetics Inc COMPOUNDS, COMPOSITIONS AND METHODS
EP1558083A4 (en) 2002-09-30 2008-04-16 Cytokinetics Inc COMPOUNDS, COMPOSITIONS AND METHODS

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001098278A1 (en) * 2000-06-21 2001-12-27 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
WO2003039460A2 (en) * 2001-11-07 2003-05-15 Merck & Co., Inc. Mitotic kinesin inhibitors

Also Published As

Publication number Publication date
US7345046B2 (en) 2008-03-18
WO2004111058A1 (en) 2004-12-23
US20050065169A1 (en) 2005-03-24
JP2007500237A (ja) 2007-01-11
KR20060054187A (ko) 2006-05-22
CN1798749A (zh) 2006-07-05
US20080069817A1 (en) 2008-03-20
CA2526217A1 (en) 2004-12-23
TW200505454A (en) 2005-02-16
MXPA05012706A (es) 2006-02-08
AU2004247650A1 (en) 2004-12-23
EP1636238A1 (en) 2006-03-22

Similar Documents

Publication Publication Date Title
CN100418971C (zh) 作为抗癌剂的杂芳基-稠合的嘧啶基化合物
EP1636225B1 (en) Pyridino 1,2-a pyrimidin-4-one compounds as anticancer agents
JP4778439B2 (ja) 抗癌剤としてのキナゾリノン化合物
US7855295B2 (en) Tetrahydrocarboline compounds as anticancer agents
JP2007512368A5 (enExample)
JP2007500237A5 (enExample)
AU2006236557A1 (en) 2-amino-quinazolin-5-ones as HSP90 inhibitors useful in treating proliferation diseases
KR20060135035A (ko) 유사분열 키네신 억제제
MXPA06005844A (en) Quinazolinone compounds as anticancer agents

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: NOVARTIS VACCINES & DIAGNOSTIC

Free format text: FORMER OWNER: CHIRON CORP.

Effective date: 20080530

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20080530

Address after: Delaware

Applicant after: Novartis Vaccines & Diagnostic Inc.

Address before: American California

Applicant before: Chiron Corporation

C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20080917

Termination date: 20110527